Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group 2025-12-15 21:00
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease 2025-12-15 18:00
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor 2025-12-15 17:00
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine 2025-12-15 17:00
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. 2025-12-15 14:06
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial 2025-12-15 08:25
Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits 2025-12-12 22:00
Global Attention: POGMENT Biomimetic Collagen "Stable Triple-Helix Breakthrough" --Unconventional and Astonishing 2025-12-12 21:46
Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD) 2025-12-12 20:00
Asia Pacific Enterprise Awards (APEA) 2025 Philippines Celebrates Visionaries Driving the Nation's Next Growth Era 2025-12-12 16:56
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial 2025-12-12 04:49
ProPharma Expands Operations with New Office in Hyderabad 2025-12-11 21:10
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025 2025-12-11 21:00
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO 2025-12-11 14:12
OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases 2025-12-11 14:00
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006 2025-12-10 22:05
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics 2025-12-10 21:00
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment 2025-12-10 17:15
DKSH Healthcare Launches Three-Part Whitepaper Series Showcasing Asia Pacific's Growing Healthcare Outsourcing Opportunity 2025-12-10 14:00
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs 2025-12-10 09:30
1 2 3 4 5 220